Status:
COMPLETED
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Lead Sponsor:
Pfizer
Conditions:
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.
Eligibility Criteria
Inclusion
- Patients with a documented diagnosis of NSCLC.
- Patients ≥ 18 years of age at initial recorded diagnosis of NSCLC.
- Patients who received treatment with alectinib during the study identification period, including those who initiated alectinib prior (index date-1) to the start of the study identification period.
- During the study observation period, patients observed with at least 2 visits after the index date-1.
Exclusion
- Receipt of treatment indicated for another primary cancer or diagnosis of another primary cancer (with the exception of non-melanotic skin cancer), within 5 years of index date-1 will be excluded.
- Patients enrolled in clinical trials prior to receiving alectinib during the study ID period (index date-1), will be included and flagged in the analysis.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT04351334
Start Date
March 1 2020
End Date
November 1 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Inc
New York, New York, United States, 10017